



### Listing of Claims:

1. (Currently Amended) Compounds of the formula (I) or (Ia),



(I)



(Ia)

in which the substituents have the following significance:

R<sub>1</sub>: C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl;

R<sub>2</sub>: C<sub>4</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>6</sub>-

alkenoyl; C<sub>3</sub>-C<sub>6</sub>-alkinoyl; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyl is C<sub>3</sub>-C<sub>6</sub>-alkenoyl; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyl is C<sub>3</sub>-C<sub>6</sub>-alkinoyl;

R<sub>3</sub>: hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; alkoxyalkyl, where alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkoxy and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>-alkyl); CO<sub>2</sub>H; CH<sub>2</sub>OH.

R<sub>4</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy where alkynyl is C<sub>2</sub>-C<sub>6</sub> alkynyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkynyl is C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>1</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy;

R<sub>5</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated

group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy, where alkynyl is C<sub>2</sub>-C<sub>6</sub> alkynyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkynyl is C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy;

X is oxygen;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkynyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, CO<sub>2</sub>H, CONH<sub>2</sub>, CO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), CONH(C<sub>1</sub>-C<sub>3</sub>-alkyl), CON(C<sub>1</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, CO(C<sub>1</sub>-C<sub>3</sub>-alkyl); amino; (C<sub>1</sub>-C<sub>3</sub>-monoalkyl)amino, (C<sub>1</sub>-C<sub>3</sub>-dialkyl)amino; C<sub>5</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>3</sub>-alkanoyl)amido, SH, SO<sub>3</sub>H, SO<sub>3</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO(C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkylthio or C<sub>1</sub>-C<sub>3</sub>-alkanoylthio,

wherein -(cyclical saturated group) is either preferably C<sub>3</sub>-C<sub>10</sub>-cycloalkyl or a ~~heterocyclic~~ heterocyclic group with 2 to 9 carbon atoms, containing further one or more heteroatoms,


**with the exception of compounds** where R<sub>1</sub> is methyl, R<sub>2</sub> is C<sub>4</sub>-C<sub>6</sub>-alkyl, R<sub>3</sub> is hydrogen or methyl, R<sub>4</sub> is hydroxy or methoxy and R<sub>5</sub> is hydroxy, methoxy or an oxygen atom bound to the carbon atom in the 5<sup>th</sup> position, ~~when X is oxygen;~~

with the further exception of compounds where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is ~~oxygen~~ hydrogen or benzyloxy and  $R_5$  is an oxygen atom bound to the carbon atom in the 5<sup>th</sup> position;


with the further exception of compounds where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is ~~oxygen~~ hydrogen, hydroxy or benzyloxy and  $R_5$  is hydroxy or methoxy;

with the further exception of compounds where  $R_2$  is  $C_1$ - $C_6$  alkenyl, when a double bond is between carbon atoms 8 and 7.

2. (Currently Amended) Compounds of the formula (IA) or (IAa),



(IA)



(IAa)

where the substituents have the following significance:

$R_1$ :  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and

alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>8</sub>-alkinyl;

wherein the two substituents R<sub>1</sub> can be the same or different;

R<sub>2</sub>: C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>8</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>6</sub>-alkenoyl; C<sub>3</sub>-C<sub>6</sub>-alkinoyl; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyl is C<sub>3</sub>-C<sub>6</sub>-alkenoyl; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyl is C<sub>3</sub>-C<sub>6</sub>-alkinoyl;

R<sub>3</sub>: hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; alkoxyalkyl, where alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkoxy and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>-alkyl); CO<sub>2</sub>H; CH<sub>2</sub>OH.

R<sub>4</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-

alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkynyl is C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy; C<sub>8</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy;

R<sub>5</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy, where alkynyl is C<sub>2</sub>-C<sub>6</sub> alkynyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkynyl is C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy;

X is oxygen;

Y<sup>-</sup> is I<sup>-</sup>, Br<sup>-</sup>, Cl<sup>-</sup>, OH<sup>-</sup> or another pharmacologically acceptable counterion;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkynyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, CO<sub>2</sub>H, CONH<sub>2</sub>, CO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), CONH(C<sub>1</sub>-C<sub>3</sub>-alkyl), CON(C<sub>1</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, CO(C<sub>1</sub>-C<sub>3</sub>-alkyl); amino; (C<sub>1</sub>-C<sub>3</sub>-monoalkyl)amino, (C<sub>1</sub>-C<sub>3</sub>-dialkyl)amino; C<sub>5</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>3</sub>-alkanoyl)amido, SH, SO<sub>3</sub>H, SO<sub>3</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO(C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkylthio or C<sub>1</sub>-C<sub>3</sub>-alkanoylthio, wherein -(cyclical saturated group) is either preferably C<sub>3</sub>-C<sub>10</sub>-cycloalkyl or a heterocyclical group with 2 to 9 carbon atoms, containing furthermore one or more heteroatoms.

3. (Currently Amended) Compounds of the formulae (I) or (IA) of Claims 1 or 2, ~~in which X is oxygen~~; R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>4</sub>-C<sub>16</sub>-cycloalkylalkyl, where cycloalkyl is C<sub>3</sub>-C<sub>10</sub> cycloalkyl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; R<sub>2</sub> is C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; R<sub>3</sub> is hydrogen or methyl; R<sub>4</sub> is hydroxy, methoxy or acetoxy.

4. (Currently amended) Compounds of the formula (IA) of Claim 2, ~~in which X is oxygen~~; R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>4</sub>-C<sub>16</sub>-cycloalkylalkyl, where cycloalkyl is C<sub>3</sub>-C<sub>10</sub> cycloalkyl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; R<sub>2</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl or C<sub>2</sub>-C<sub>6</sub>-alkenyl, R<sub>3</sub> is hydrogen or methyl; R<sub>4</sub> is hydroxy, methoxy or acetoxy.

5. (Currently Amended) Compounds of Claims 1 or 2, selected from:  
17-allyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -

methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy)morphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-



14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-methoxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5α-epoxy-3-hydroxy-5β-methyl-14β-(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(2-methylbenzyl)oxy]morphinan-6-one, 14β-[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5α-epoxy-3-hydroxymorphinan-6-one, 14β-benzyloxy-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxymorphinan-6-one, 14β-butoxy-17-cyclopropylmethyl-4,5α-epoxy-3-hydroxymorphinan-6-one, 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-[(3-methylbutyl)oxy]morphinan-6-one, 4,5α-epoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]-3-[(prop-2-ynyl)oxy]morphinan-6-one, 14β-[(3-chlorobenzyl)oxy]-4,5α-epoxy-17-methyl-3-[(prop-2-ynyl)oxy]morphinan-6-one, 4,5α-epoxy-17-ethyl-3-methoxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-17-ethyl-3-hydroxy-14β-[(3-phenylpropyl)oxy]morphinan-6-one, 4,5α-epoxy-3-hydroxy-14β-[(3-methylbutyl)oxy]-17-propylmorphinan-6-one, 5β-benzyl-14-methoxycodeinone (= 5-benzyl-7,8-didehydro-4,5α-epoxy-3,14β-dimethoxy-17-methyl-morphinan-6-one), 5β-benzyl-4,5α-epoxy-3,14β-dimethoxy-17-methylmorphinan-6-one, 5β-benzyl-4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 14β-benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one, 14β-benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14β-[(2-naphthylmethyl)oxy]morphinan-6-one, 3,4-dimethoxy-17-methyl-14β-[(2-naphthylmethyl)oxy]morphinan-6-one, 4-hydroxy-3-methoxy-5β,17-dimethyl-14β-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-5β,17-dimethyl-14β-[(3-

phenylpropyl)oxy]-morphinan-6-one, 14 $\beta$ -ethoxy-4-hydroxy-3-methoxy-5 $\beta$ ,17-  
 dimethylmorphinan-6-one, 14 $\beta$ -ethoxy-3,4-dimethoxy-5 $\beta$ ,17-dimethylmorphinan-6-one, 14 $\beta$ -  
 benzyloxy-3,4-dimethoxy-5 $\beta$ ,17-dimethylmorphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-17,17-  
 dimethyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, (17S)-4,5 $\alpha$ -epoxy-17-ethyl-3-  
 hydroxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, (17R)-4,5 $\alpha$ -epoxy-  
 3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofuran-2-  
 yl)methyl]morphinan-6-one, (17R)-17-allyl-4,5 $\alpha$ -epoxy-14 $\beta$ -ethoxy-3-hydroxy-17-methyl-  
 6-oxomorphinan-6-one, (17R)-17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-  
 oxomorphinan-6-one, (17S)-17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-  
 oxomorphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17,17-dimethyl-6-oxo-  
 morphinan-6-one, 5 $\beta$ -benzyl-14 $\beta$ -(butoxy)-4,5-epoxy-3-hydroxy-17,17-dimethyl-6-  
 oxomorphinan-6-one, (17S)-17-allyl-5 $\beta$ -benzyl-14 $\beta$ -butoxy-4,5 $\alpha$ -epoxy-3-hydroxy-17-  
 methyl-6-oxomorphinan-6-one, 14 $\beta$ -butoxy-4,5 $\alpha$ -epoxy-3-hydroxy-17,17-dimethyl-6-  
 oxomorphinan-6-one, (17R)-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-  
 oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, (17R)-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-  
 3-methoxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, (17R)-17-  
 cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(2-  
 phenylbenzyl)oxy]morphinan-6-one, (17R)-14 $\beta$ -[(4-chlorobenzyl)oxy]-17-  
 cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxomorphinan-6-one, 17(R)-4,5 $\alpha$ -  
 epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-oxo-17-(2-phenylethyl)morphinan-6-one, 4,5 $\alpha$ -  
 epoxy-3-methoxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
 4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
 4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,

4,5 $\alpha$ -epoxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
17-(cyclopropylmethyl)-4,5 $\alpha$ -epoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
4,5 $\alpha$ -epoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
17-(cyclopropylmethyl)-4-hydroxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
17-(cyclopropylmethyl)-4-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one,  
4-(n-butyloxy)-17-(cyclopropylmethyl)-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, and a or  
~~any~~ pharmaceutically acceptable salt thereof ~~or easily accessible derivative of it.~~

6. (Previously Presented) A pharmaceutical composition, comprising a compound of Claims 1 or 2 and/or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier substance.

Claim 7 (Cancelled).

8. (Currently Amended) A method ~~of using a compound of Claims 1 or 2 for the treatment of~~ treating pain, ~~including chronic and acute pain, post operative pain,~~ rheumatic diseases (e.g. arthritis), ileus, obstipation, overweight, or addiction, ~~including opioid, cocaine and alcohol addiction as well as for the manufacture of a narcotic~~ comprising the step of administering to a patient in need thereof with an effective amount of the compound of claim 1 or 2.

9. (Currently Amended) Compounds according to Claim 1 or 2, wherein R<sub>5</sub> is OH or ~~alkoxy~~ alkyloxy.

10. (Previously Presented) Compounds according to Claim 1 or 2, wherein R<sub>3</sub> is hydrogen, alkyl or aralkyl, preferably hydrogen or alkyl.

11. (Currently Amended) Compounds according to Claim 1 or 2, wherein R<sub>4</sub> is OH, ~~alkoxy~~ alkyloxy or alkenyloxy or alkynyloxy.

12. (Previously Presented) Compounds according to Claim 1 or 2, wherein a single bond is present between the carbon atoms of the numbers 7 and 8.

13. (Previously Presented) Compounds according to Claim 1 or 2, wherein R<sub>2</sub> is alkyl or aralkyl, preferably aralkyl.

14. (Previously Presented) Compounds according to Claim 1 or 2, wherein R<sub>1</sub> is alkyl, (cyclical saturated group)alkyl, aralkyl or alkenyl.

15. (Currently Amended) Compounds according to Claim 1 or 2, wherein R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl.